MRTX1719

Phase 1Small molecule

Bristol-Myers Squibb

MRTX1719 is one of 62 small molecule programs targeting Advanced Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced CancerRecruiting

MesotheliomaRecruiting

Advanced CancerPhase 1

Recruiting

MesotheliomaPhase 1

Recruiting

Competition

Competitive Landscape

67 competitors in Advanced Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

12 2

Keytruda

Merck & Co.

Phase 2

12 3

Camptosar

Pfizer

Phase 2

8 4

Gemzar

Johnson & Johnson

Phase 2

8 5

Opdivo

Bristol-Myers Squibb

Phase 2

6 6

Verzenio

Eli Lilly

Phase 2

4 7

Elunate

Takeda

Phase 2

1 8

Taxotere

AAvyxa

Phase 2

9 9

Paraplatin

AAvyxa

Phase 2

5 10

Torisel

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Mesothelioma

NCT05245500

Q1 2032

Phase 1Recruiting

Advanced Cancer

NCT07382544

Clinical

Trials by Indication[1]

Mesothelioma1 trial

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05245500·336 enrolled

Advanced Cancer1 trial

Phase 1b Trial of Combined PRMT5 Inhibition With BMS-986504 and PARP Inhibition With Olaparib in Patients With Advanced Cancer With MTAP Loss

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07382544·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MRTX1719. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MRTX1719 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MRTX1719. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Bristol-Myers Squibb

MRTX1719

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2032

Trials by Indication[1]

Mesothelioma1 trial

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News